Core Viewpoint - The company, Hema Medical (03309.HK), announced a share buyback on September 4, 2023, spending HKD 355,000 to repurchase 188,000 shares [1] Company Summary - Hema Medical executed a buyback of 188,000 shares at a cost of HKD 355,000 on September 4, 2023 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 希瑪醫療控股有限公司 呈交日期： 2025年9月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 希瑪醫療控股有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.1 | HKD | | 800,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.1 | HKD | | 800,000,000 | 本月底法定/註冊股本 ...

Core Viewpoint - Hema Medical (03309) reported a revenue increase of 2.4% year-on-year, driven by rising demand for ophthalmic medical services in Hong Kong, despite competitive pressures in Shenzhen affecting dental and ophthalmic service revenues [1] Financial Performance - Revenue for the first half of 2025 reached HKD 944 million, reflecting a year-on-year growth of 2.4% [1] - Profit attributable to equity holders amounted to HKD 49.94 million, showing a significant year-on-year increase of 62.4% [1] Market Dynamics - The growth in revenue was primarily attributed to increased demand for ophthalmic services in the Hong Kong market, which was partially offset by decreased revenues in Shenzhen due to intense competition in dental and ophthalmic services [1] Acquisition Announcement - Hema Medical announced the acquisition of 58% of the issued share capital of Hong Kong Endoscopy Examination and Treatment Centre Limited, which operates under the name "Hong Kong Endoscopy Centre" [1] - The acquisition is expected to be completed around October 2025 [1]

Core Viewpoint - Hema Medical (03309) reported a 6.5% increase in stock price, reaching HKD 2.13, with a trading volume of HKD 6.7167 million following the release of its mid-year results for 2025 [1] Financial Performance - The company reported revenue of HKD 944 million for the first half of 2025, representing a year-on-year growth of 2.4% [1] - Profit attributable to equity holders was HKD 49.944 million, showing a significant year-on-year increase of 62.4% [1] Market Dynamics - The slight increase in revenue was attributed to rising demand for ophthalmic medical services in Hong Kong, which boosted revenue from ophthalmic services [1] - However, this growth was partially offset by a decline in revenue from dental and ophthalmic services in Shenzhen due to intense competition [1] Acquisition Announcement - Hema Medical announced an agreement to acquire 58% of the issued share capital of Hong Kong Endoscopy Examination and Treatment Centre Limited, which operates under the name "Hong Kong Endoscopy Centre" [1] - The acquisition is expected to be completed around October 2025 [1]

Group 1 - The company, Hema Medical (03309.HK), announced the acquisition of 58% of the issued share capital of Hong Kong Endoscopy Examination and Treatment Centre Limited, which operates under the name "Hong Kong Endoscopy Centre" [1] - The acquisition is expected to be completed around October 2025 [1] - As of August 26, 2025, Hema Medical's stock closed at HKD 2.0, down 1.48%, with a trading volume of 1.198 million shares and a turnover of HKD 2.3911 million [1] Group 2 - Hema Medical has a market capitalization of HKD 2.531 billion, ranking 15th in the medical services sector [1] - Key financial metrics for Hema Medical compared to the industry average are as follows: - ROE: -7.51% vs. -0.96% (Industry Rank: 40) [1] - Market Capitalization: HKD 2.531 billion vs. HKD 8.349 billion (Industry Rank: 15) [1] - Revenue: HKD 1.913 billion vs. HKD 3.838 billion (Industry Rank: 16) [1] - Net Profit Margin: -5.66% vs. -850.54% (Industry Rank: 40) [1] - Gross Margin: 27.58% vs. 37.38% (Industry Rank: 32) [1] - Risk Rate: 30.52% vs. 70.69% (Industry Rank: 22) [1]

Core Insights - The company reported a revenue of HKD 944 million for the six months ending June 30, 2025, representing a year-on-year increase of 2.4% [1] - Gross profit reached HKD 294 million, up 1.7% year-on-year [1] - Profit attributable to equity holders increased significantly by 62.4% to HKD 49.94 million [1] - Adjusted profit attributable to equity holders rose by 74.5% to HKD 69.64 million [1] - Basic earnings per share were HKD 0.0411 [1] Revenue Breakdown - The slight increase in total revenue was primarily driven by a growing demand for ophthalmic medical services in the Hong Kong market [1] - Revenue growth from Hong Kong ophthalmic services was partially offset by a decline in revenue from dental and ophthalmic services in Shenzhen due to intense competition [1]

Core Viewpoint - The company reported a slight increase in revenue driven by the growing demand for ophthalmic medical services in Hong Kong, although this was partially offset by a decrease in revenue from dental and ophthalmic services in Shenzhen due to intense competition [1] Financial Performance - Revenue for the six months ending June 30, 2025, was HKD 944 million, representing a year-on-year growth of 2.4% [1] - Profit attributable to equity holders was HKD 49.944 million, showing a significant year-on-year increase of 62.4% [1] - Basic earnings per share were HKD 0.0411 [1] Market Dynamics - The increase in revenue was primarily attributed to the rising demand for ophthalmic services in the Hong Kong market [1] - The decline in revenue from Shenzhen's dental and ophthalmic services was a result of fierce competition in that region [1]

Core Viewpoint - The company, Hema Medical (03309.HK), announced the acquisition of 58% of the issued share capital of Hong Kong Endoscopy Centre Limited, which will become a subsidiary upon completion of the transaction expected around October 2025 [1] Group 1: Acquisition Details - The acquisition agreement was signed with three individual sellers [1] - Hong Kong Endoscopy Centre, established in 2016, operates three endoscopy examination rooms and provides specialized medical services including gastroscopy, colonoscopy, and cystoscopy [1] - The acquisition aims to enhance the company's medical services in Hong Kong and leverage existing patient bases for synergistic effects with its operations in Hong Kong and cross-border business in Shenzhen [1] Group 2: Market Position and Strategy - The company has been actively seeking to expand its market opportunities to meet the demand for high-quality medical services [1] - Hong Kong Endoscopy Centre has a strong reputation in Hong Kong, with advantages in management, quality medical services, and financial performance [1]

Core Viewpoint - The company, Hema Medical (03309), announced the acquisition of 58% of the issued share capital of Hong Kong Endoscopy Centre Limited, which will become a subsidiary upon completion of the acquisition expected around October 2025 [1] Group 1: Acquisition Details - The acquisition agreement was signed with three individual sellers on August 26, 2025 [1] - Hong Kong Endoscopy Centre, established in 2016, operates three endoscopy examination rooms and provides specialized medical services including gastroscopy, colonoscopy, and cystoscopy [1] - The acquisition aims to meet the market demand for high-quality medical services and is expected to enhance the company's presence in Hong Kong [1] Group 2: Strategic Rationale - The company believes that Hong Kong Endoscopy Centre has advantages in management, quality medical services, and financial performance [1] - The acquisition is anticipated to create synergies with the company's existing patient base and operations in Hong Kong and Shenzhen [1] - The board of directors considers the acquisition to be in the overall interest of the company and its shareholders [1]